REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:53 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Finasteride
Disease:  Benign Prostatic Hyperplasia
Target:   5α-reductase

EVIDENCE GRADE: Approved
Confidence Score: 95%
Evidence Level: Level 1 (RCT + regulatory approval)
Trial Phase: Phase III

MECHANISM
---------
DHT reduction decreases prostate volume and improves urinary flow.

OUTCOMES
--------
Reduced prostate volume, improved symptom scores vs placebo.

AI SUMMARY (generated March 15, 2026)
-----------
Finasteride is FDA-approved for BPH with Phase III PLESS trial evidence demonstrating symptom and volume benefits. 5α-reductase mechanism directly addresses disease pathophysiology.

KNOWN RISKS
-----------
• Sexual dysfunction
• Depression (reported, debated incidence)
• PSA reduction (masking prostate cancer screening)
• Contraindicated in pregnancy (teratogenic)

CITATIONS
---------
[PUBMED] 7688365: Finasteride in benign prostatic hyperplasia (PLESS)
  https://pubmed.ncbi.nlm.nih.gov/7688365/

[CLINICALTRIALS] NCT00021880: PLESS trial
  https://clinicaltrials.gov/study/NCT00021880

[FDA] 020180: Proscar (finasteride)
  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020180

PUBMED IDs: 7688365
CLINICAL TRIAL IDs: NCT00021880

LAST VERIFIED: June 24, 2026
LAST UPDATED:  June 24, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode